MAZE: Ascending Triangle detected on 11 Mar 2026

MAZE is forming an ascending triangle following a strong flat base established in January 2026 and three-white-soldiers reversal on March 6. The pattern shows exceptional technical structure with a 15.0/15 structure score and 13.0/13 breakout score, indicating tight consolidation around resistance at $49.41 with support anchored at $44.79. Current price sits at $51.06, positioning just above resistance. Volume is notably elevated at 2.89x average with 1.29M shares traded, reflecting strong institutional accumulation. The overall pattern quality scores 87.8/98, with an exceptionally high 75.99% win probability, suggesting this setup has historically strong technical merit.

Maze announced a $150 million oversubscribed private placement in September 2025 and positive Phase 1 results for MZE782 establishing proof of mechanism. Initial topline Phase 2 data for MZE829 is expected by end of Q1 2026. Mizuho initiated coverage with an Outperform rating and $97 price target, modeling approximately $8 billion in combined peak revenue for the two lead programs at a 40% probability of success. Guggenheim raised its price target to $46 from $34 based on Phase 1 data suggesting MZE782 applicability in CKD with Phase 2 study planned for 2026. The company reported $167.5 million in 2024 license revenue and $196.8 million cash position with runway into H2 2027. This confluence of positive clinical catalysts and bullish analyst coverage is driving the recent uptrend.

A successful breakout above $49.41 resistance would target $53.63 conservatively, representing approximately 5.1% upside from current levels. The ascending triangle structure suggests continuation momentum could extend further given the pattern's symmetry and breakout quality score. Volume confirmation is critical—sustained volume above 800K shares would validate the move. The pattern invalidates decisively below support at $44.79, which would represent a -12.2% breakdown and loss of the bullish structure entirely. Win probability of 75.99% indicates this pattern has historically resolved higher more often than not.

Harold Bernstein, President R&D and Chief Medical Officer, exercised and sold 15,000 shares on February 2, 2026, fully divesting his direct ownership, though this was part of a 10b5-1 trading plan and he still holds nearly 300,000 stock options. RSI at 64.78 approaches overbought territory (70), signaling potential momentum exhaustion. The stock has delivered 283% gain over the past year and 181% in six months, while InvestingPro analysis indicates the stock appears overvalued relative to Fair Value estimates. Biotech sector regime is bearish (-0.23), creating headwinds. Clinical execution risk remains the primary catalyst—delayed Q1 2026 MZE829 data or negative Phase 2 HORIZON results could trigger sharp reversal. Stock volatility at 62.16% is elevated; beta of 0.76 provides some downside protection but high daily swings (ATR 5.27%) create whipsaw risk around the $49.41 level.